About
Copy Link
Titles
Assistant Professor
Biography
Dr. William Kim has demonstrated a passion for interdisciplinary collaboration. His research leverages advanced computational and data-driven approaches alongside genome engineering technologies to contribute to advancing our understanding of cancer. Kim received his PhD from Duke University and the Institute for Genome Sciences Policy, where he received support from the Department of Defense Breast Cancer Research Predoctoral Program and the Korean Science & Engineering Foundation Award.
Following his doctoral work, Kim joined the Dana Farber Cancer Institute and the Broad Institute of Harvard and MIT for his postdoctoral research. There, he made significant contributions to developing novel computational approaches for the systematic characterization of cancer genomes and oncogenic cellular states. He also discovered a novel role for the Protein phosphatase 2A (PP2A) enzyme in oncogenic transformation, expanding the understanding of this important signaling pathway.
Leveraging his expertise in cancer biology and computational biology, Kim then joined the University of California San Diego (UCSD) School of Medicine in the Division of Genomics and Precision Medicine. At UCSD, he co-led a multidisciplinary team of researchers, clinicians, patients, and community advocates on a California Initiative for Precision Medicine Project, supported by the California Governor's Office. Kim also served as the Co-Director of the UCSD Center for Cancer Target Discovery and Development (CTD2), further driving the integration of data-driven and biological approaches to cancer research.
William Kim joined the Department of Urology at Yale University School of Medicine. Here, he aims to bridge the gap between cancer biology and data science, working towards a comprehensive understanding of cellular circuitry and the realization of the full potential of cancer precision medicine.
Appointments
Urology
Assistant ProfessorPrimary
Other Departments & Organizations
Research
Copy Link
Overview
The Kim lab employs systematic approaches to study cancer, with the goal of discovering the most effective strategies for prevention and treatment. Our methodology involves 1) comprehensive assessment of oncogenic programs in cancers using integrated machine-learning techniques, 2) deep interrogation of molecular changes in response to pharmacological and genetic perturbations, and 3) reconstruction and reverse engineering of cancer cells to create better models of the disease. These approaches will enhance our understanding of cancer as a complex system, ultimately guiding the development of strategies that maximize therapeutic efficacy while minimizing drug resistance and disease recurrence in patients.
Medical Research Interests
Public Health Interests
ORCID
0000-0002-3021-7193
Research at a Glance
Research Interests
Neoplasms
Biomarkers, Tumor
Computational Biology
Cell Transformation, Neoplastic
Precision Medicine
Publications
2025
Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer
Jiang X, Ma X, Zhou Y, Liu X, Zhang T, Kim W, Balachandran S, Cañadas I. Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer. Cell Reports 2025, 44: 116384. PMID: 41046514, DOI: 10.1016/j.celrep.2025.116384.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer
Murayama T, Mahadevan N, Meador C, Ivanova E, Pan Y, Knelson E, Tani T, Nakayama J, Ma X, Thai T, Hung Y, Kim W, Watanabe H, Cai K, Hata A, Paweletz C, Barbie D, Cañadas I. Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer. Cancer Research Communications 2024, 4: 2399-2414. PMID: 39177280, PMCID: PMC11391691, DOI: 10.1158/2767-9764.crc-24-0360.Peer-Reviewed Original ResearchCitationsAltmetricTargeting DHX9 triggers tumor-intrinsic interferon response and replication stress in Small Cell Lung Cancer
Murayama T, Nakayama J, Jiang X, Miyata K, Morris A, Cai K, Prasad R, Ma X, Efimov A, Belani N, Gerstein E, Tan Y, Zhou Y, Kim W, Maruyama R, Campbell K, Chen L, Yang Y, Balachandran S, Canadas I. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in Small Cell Lung Cancer. Cancer Discovery 2024, 14: 468-491. PMID: 38189443, PMCID: PMC10905673, DOI: 10.1158/2159-8290.cd-23-0486.Peer-Reviewed Original ResearchCitationsAltmetric
2023
Activation of KrasG12D in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma
Chaudhary P, Xu X, Wang G, Hoj J, Rampersad R, Asselin-Labat M, Ting S, Kim W, Tamayo P, Pendergast A, Onaitis M. Activation of KrasG12D in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma. Cancer Research Communications 2023, 3: 2400-2411. PMID: 37882674, PMCID: PMC10668634, DOI: 10.1158/2767-9764.crc-22-0408.Peer-Reviewed Original ResearchCitationsAltmetricDeciphering the Functional Roles of Individual Cancer Alleles Across Comprehensive Cancer Genomic Studies.
Ma JY, Ting S, Tam B, Pham T, Reich M, Mesirov J, Tamayo P, Kim W. Deciphering the Functional Roles of Individual Cancer Alleles Across Comprehensive Cancer Genomic Studies. BioRxiv 2023 PMID: 38014215, DOI: 10.1101/2023.11.14.567106.Publications for non-academic audiencesTargeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy
Steen E, Basilaia M, Kim W, Getz T, Gustafson J, Zage P. Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy. Biochemical Pharmacology 2023, 216: 115751. PMID: 37595672, PMCID: PMC10911250, DOI: 10.1016/j.bcp.2023.115751.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricTargeting TBK1 to overcome resistance to cancer immunotherapy
Sun Y, Revach O, Anderson S, Kessler E, Wolfe C, Jenney A, Mills C, Robitschek E, Davis T, Kim S, Fu A, Ma X, Gwee J, Tiwari P, Du P, Sindurakar P, Tian J, Mehta A, Schneider A, Yizhak K, Sade-Feldman M, LaSalle T, Sharova T, Xie H, Liu S, Michaud W, Saad-Beretta R, Yates K, Iracheta-Vellve A, Spetz J, Qin X, Sarosiek K, Zhang G, Kim J, Su M, Cicerchia A, Rasmussen M, Klempner S, Juric D, Pai S, Miller D, Giobbie-Hurder A, Chen J, Pelka K, Frederick D, Stinson S, Ivanova E, Aref A, Paweletz C, Barbie D, Sen D, Fisher D, Corcoran R, Hacohen N, Sorger P, Flaherty K, Boland G, Manguso R, Jenkins R. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature 2023, 615: 158-167. PMID: 36634707, PMCID: PMC10171827, DOI: 10.1038/s41586-023-05704-6.Peer-Reviewed Original ResearchCitationsAltmetric
2022
MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer
Yoshida R, Saigi M, Tani T, Springer B, Shibata H, Kitajima S, Mahadevan N, Campisi M, Kim W, Kobayashi Y, Thai T, Haratani K, Yamamoto Y, Sundararaman S, Knelson E, Vajdi A, Canadas I, Uppaluri R, Paweletz C, Miret J, Lizotte P, Gokhale P, Jänne P, Barbie D. MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer. Cancer Research 2022, 82: 4079-4092. PMID: 36066413, PMCID: PMC9627131, DOI: 10.1158/0008-5472.can-22-0770.Peer-Reviewed Original ResearchCitationsAltmetricCHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity
Bernareggi D, Xie Q, Prager B, Yun J, Cruz L, Pham T, Kim W, Lee X, Coffey M, Zalfa C, Azmoon P, Zhu H, Tamayo P, Rich J, Kaufman D. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. Nature Communications 2022, 13: 1899. PMID: 35393416, PMCID: PMC8990014, DOI: 10.1038/s41467-022-29469-0.Peer-Reviewed Original ResearchCitationsAltmetric
2021
An expanded universe of cancer targets
Hahn W, Bader J, Braun T, Califano A, Clemons P, Druker B, Ewald A, Fu H, Jagu S, Kemp C, Kim W, Kuo C, McManus M, B. Mills G, Mo X, Sahni N, Schreiber S, Talamas J, Tamayo P, Tyner J, Wagner B, Weiss W, Gerhard D, Dancik V, Gill S, Hua B, Sharifnia T, Viswanathan V, Zou Y, Dela Cruz F, Kung A, Stockwell B, Boehm J, Dempster J, Manguso R, Vazquez F, Cooper L, Du Y, Ivanov A, Lonial S, Moreno C, Niu Q, Owonikoko T, Ramalingam S, Reyna M, Zhou W, Grandori C, Shmulevich I, Swisher E, Cai J, Chan I, Dunworth M, Ge Y, Georgess D, Grasset E, Henriet E, Knútsdóttir H, Lerner M, Padmanaban V, Perrone M, Suhail Y, Tsehay Y, Warrier M, Morrow Q, Nechiporuk T, Long N, Saultz J, Kaempf A, Minnier J, Tognon C, Kurtz S, Agarwal A, Brown J, Watanabe-Smith K, Vu T, Jacob T, Yan Y, Robinson B, Lind E, Kosaka Y, Demir E, Estabrook J, Grzadkowski M, Nikolova O, Chen K, Deneen B, Liang H, Bassik M, Bhattacharya A, Brennan K, Curtis C, Gevaert O, Ji H, Karlsson K, Karagyozova K, Lo Y, Liu K, Nakano M, Sathe A, Smith A, Spees K, Wong W, Yuki K, Hangauer M, Kaufman D, Balmain A, Bollam S, Chen W, Fan Q, Kersten K, Krummel M, Li Y, Menard M, Nasholm N, Schmidt C, Serwas N, Yoda H, Ashworth A, Bandyopadhyay S, Bivona T, Eades G, Oberlin S, Tay N, Wang Y, Weissman J. An expanded universe of cancer targets. Cell 2021, 184: 1142-1155. PMID: 33667368, PMCID: PMC8066437, DOI: 10.1016/j.cell.2021.02.020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetric
Get In Touch
Copy Link
Contacts
Administrative Support
Locations
Fitkin Memorial Pavilion
Academic Office
789 Howard Avenue
New Haven, CT 06519
Brady Memorial Laboratory
Lab
310 Cedar St
New Haven, CT 06510